Seco Elena M, Fotso Serge, Laatsch Hartmut, Malpartida Francisco
Centro Nacional de Biotecnología, Campus de la Universidad Autónoma de Madrid, Cantoblanco, Spain.
Chem Biol. 2005 Oct;12(10):1093-101. doi: 10.1016/j.chembiol.2005.08.007.
We recently characterized rimocidin B (3b) and CE-108B (4b) as two polyene amides with improved pharmacological properties, produced by genetically modified Streptomyces diastaticus var. 108. In this work, genetic and biochemical analysis of the producer strain show that the two amides are derived from the parental polyenes rimocidin (3a) and CE-108 (4a) by a post-PKS modification of the free side chain carboxylic acid. This modification is mediated by an amidotransferase activity operating after the biosynthesis of rimocidin (3a) and CE-108 (4a) are completed. Two polyenes, intermediates of the biosynthetic pathway of rimocidin (3a) and CE-108 (4a), were also isolated and shown to have some improved pharmacological properties compared with the final products.
我们最近鉴定出龟裂杀菌素B(3b)和CE - 108B(4b)是两种具有改善药理特性的多烯酰胺,由基因改造的淀粉酶链霉菌变种108产生。在这项工作中,对生产菌株的遗传和生化分析表明,这两种酰胺是通过游离侧链羧酸的聚酮合酶后修饰,从亲本多烯龟裂杀菌素(3a)和CE - 108(4a)衍生而来。这种修饰是由一种酰胺转移酶活性介导的,该活性在龟裂杀菌素(3a)和CE - 108(4a)的生物合成完成后起作用。还分离出了两种多烯,它们是龟裂杀菌素(3a)和CE - 108(4a)生物合成途径的中间体,并且显示出与最终产物相比具有一些改善的药理特性。